Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa)

Cancer Radiother. 2021 Jun;25(4):400-409. doi: 10.1016/j.canrad.2020.11.004. Epub 2021 Jan 18.

Abstract

Systematic review for the treatment of high-risk prostate cancer (HR-PCa, D'Amico classification risk system) with external body radiation therapy (EBRT)+brachytherapy-boost (BT-boost) or with EBRT+stereotactic body RT-boost (SBRT-boost). In March 2020, 391 English citations on PubMed matched with search terms "high risk prostate cancer boost". Respectively 9 and 48 prospective and retrospective studies were on BT-boost and 7 retrospective studies were on SBRT-boost. Two SBRT-boost trials were prospective. Only one study (ASCENDE-RT) directly compared the gold standard treatment [dose-escalation (DE)-EBRT+androgen deprivation treatment (ADT)] versus EBRT+ADT+BT-boost. Biochemical control rates at 9 years were 83% in the experimental arm versus 63% in the standard arm. Cumulative incidence of late grade 3 urinary toxicity in the experimental arm and in the standard arm was respectively 18% and 5%. Two recent studies with HR-PCa (National Cancer Database) demonstrated better overall survival with BT-boost (low dose rate LDR or high dose rate HDR) compared with DE-EBRT. These recent findings demonstrate the superiority of EBRT+BT-boost+ADT versus DE-EBRT+ADT for HR-PCa. It seems that EBRT+BT-boost+ADT could now be considered as a gold standard treatment for HR-PCa. HDR or LDR are options. SBRT-boost represents an attractive alternative, but the absence of randomised trials does not allow us to conclude for HR-PCa. Prospective randomised international phase III trials or meta-analyses could improve the level of evidence of SBRT-boost for HR-PCa.

Keywords: Brachytherapy; Brachytherapy boost; Cancer de la prostate; Cancer de la prostate à haut risque; Curiethérapie; High-risk prostate cancer; Prostate cancer; Radiothérapie corporelle stéréotaxique; Stereotactic body radiation therapy; Stereotactic body radiation therapy boost; Stimulation de la curiethérapie; Stimulation de la radiothérapie corporelle stéréotaxique.

Publication types

  • Systematic Review

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Brachytherapy / adverse effects
  • Brachytherapy / methods*
  • Clinical Trials as Topic
  • Combined Modality Therapy / methods
  • Dose Fractionation, Radiation
  • Humans
  • Male
  • Prospective Studies
  • Prostatic Neoplasms / radiotherapy*
  • Radiation Dose Hypofractionation
  • Radiosurgery / adverse effects
  • Radiosurgery / methods*
  • Retrospective Studies

Substances

  • Androgen Antagonists